Raytheon awarded $71 million in Navy contracts for missile systems
LONDON - Partners Group Private Equity Limited (LSE:PEYS/PEY) announced Tuesday it has agreed to exit its longstanding investment in PCI Pharma Services while reinvesting a portion to maintain a minority position in the company.
The transaction values PGPE’s stake in PCI at approximately €83 million, aligning with the company’s latest published carrying value as of May 31. PGPE will reinvest about €18 million to retain participation in the pharmaceutical contract development and manufacturing organization’s future growth.
A consortium led by Bain Capital and Kohlberg & Company will acquire a majority stake in PCI Pharma Services as part of the deal, which is expected to close in the second half of 2025, subject to regulatory approvals.
Partners Group initially invested in PCI in 2016, helping transform it from a regional commercial packaging organization into a global contract development and manufacturing organization. In 2020, Kohlberg & Company and Mubadala Investment Company acquired a majority stake while Partners Group maintained a minority position.
"During this phase of ownership, PCI expanded into advanced drug delivery services, development and manufacturing of biologics, and sterile fill-finish services," according to the company statement.
PCI Pharma Services, founded in 2012 and headquartered in Philadelphia, Pennsylvania, currently represents the second largest investee company in PGPE’s portfolio.
PGPE, formerly known as Princess Private Equity Holding Limited, is an investment holding company domiciled in Guernsey that invests in private equity direct investments and is managed by Partners Group.
The information was disclosed in a press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.